Menarini Receives European Commission Approval of ELZONRIS (tagraxofusp), for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
– ELZONRIS is the first approved treatment for patients with BPDCN, and the first approved CD123-targeted therapy, in Europe – Approval is based on the results of the largest prospective clinical trial ever conducted in patients with treatment-naïve or previously-treated BPDCN The Menarini Group, a privately held Italian pharmaceutical and diagnostics company, announced today that […]
